Drug Trial Radar · NCT06863961
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
162
Actual
Start
Apr 1, 2025
Primary completion
Jul 22, 2026
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
AfimkibartDrug
Afimkibart will be administered as SC injection.
PlaceboDrug
Placebo will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who Achieve Eczema Area and Severity Index-75 (EASI-75) Response (>= 75% Improvement from Baseline) at Week 16Time frame: Baseline and Week 16
Locations
52 sites in 8 countries. Site status is shown where the registry gives one.
First OC Dermatology
Fountain Valley, California
UCLA Division of Dermatology
Los Angeles, California
Dermatology Research Associate
Los Angeles, California
Olympian Clinical Research
Tampa, Florida
Hamilton Research, LLC
Alpharetta, Georgia
Dermatology Affiliates Research Institute, LLC
Atlanta, Georgia
Dawes Fretzin Clinical Res LLC
Indianapolis, Indiana
Southern Indiana Clinical Trials
New Albany, Indiana
Revival Research Institute, LLC
Troy, Michigan
Regents of the University of Minnesota
Minneapolis, Minnesota
Care Access Research - Hoboken
Hoboken, New Jersey
Centricity Research Columbus Dermatology
Columbus, Ohio
Central Sooner Research
Oklahoma City, Oklahoma
Oregon Health & Science University
Portland, Oregon
Best Skin Research LLC
Camp Hill, Pennsylvania
Cumberland Skin Center for Clinical Research LLC
Hermitage, Tennessee
Arlington Research Center
Arlington, Texas
Modern Research Associates
Dallas, Texas
Reveal Research Institute
Dallas, Texas
Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A
Rio de Janeiro, Brazil
Clinica Ibis
Salvador, Estado de Bahia, Brazil
Centro de Estudos em Terapias Inovadoras ? CETI
Curitiba, Paraná, Brazil
Hospital de Clnicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
Botucatu, São Paulo, Brazil
Centro de Pesquisa São Lucas
Campinas, São Paulo, Brazil
HMCG - Hospital e Maternidade Dr. Christovo da Gama
Santo Andr, São Paulo, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
Sao Jose Rio Preto, São Paulo, Brazil
Centre de Recherche Saint-Louis
Québec, Canada
Centricity Research London Victoria
London, Ontario, Canada
DermEffects
London, Ontario, Canada
Lynderm Research Inc
Markham, Ontario, Canada
DermEdge
Mississauga, Ontario, Canada
Hopital Saint Louis
Cedex 10, Paris, France
Dermatologikum Hamburg GmbH
Hamburg, Germany
Klinisches Studienzentrum
Bad Bentheim, Lower Saxony, Germany
DRK Krankenhaus Chemnitz-Rabenstein
Chemnitz, Saxony, Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Emilia-Romagna, Italy
Fondazione IRCCS CA? Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
Azienda Ospedaliero Universitaria Policlinico Gaspare Rodolico - San Marco (Presidio G. Rodolico)
Catania, Sicily, Italy
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.